2026-01-22 - Analysis Report
# AbbVie (ABBV) Financial Report

## Simple Numbers
- **Cumulative Return (ABBV)**: 177.76%
- **Cumulative Return (S&P 500, VOO)**: 91.55%
- **Divergence**: 82.20 (current)
- **Relative Divergence**: 65.80%
  
### Moving Average Prices
- **Close Price**: $216.15
- **5-day SMA**: $216.64
- **20-day SMA**: $224.03
- **60-day SMA**: $225.36
  
### Market Indicators
- **Market Risk Indicator (MRI)**: 0.80 (Medium Investment)
- **RSI**: 36.31
- **PPO**: -0.53
- **Expected Return**: 40.20%
  
### Analyst Consensus
```text
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 245.22 / 289.00 / 184.00
```

## Company Overview
AbbVie is a global biopharmaceutical company focused on developing innovative therapies for complex diseases.

## Analysis
- **Cumulative Return Comparison**: AbbVie's cumulative return significantly outperformed the S&P 500, indicating strong growth of 86.21% more than the index.
- **Divergence**: The divergence of 82.20 suggests a favorable position for AbbVie relative to historical performance.
- **Moving Averages**: Recent price behavior shows that the current price is below the 5-day, 20-day, and 60-day SMAs, indicating a potential downward trend.
- **Market Indicators**: The MRI of 0.80 suggests a medium risk investment, while the RSI of 36.31 indicates that the stock may be oversold. The negative PPO reflects a bearish trend.
- **Expected Return**: An expected return of 40.20% if invested long-term suggests potential for substantial gains.
  
### Recent News
- AbbVie is focusing on the obesity-treatment market, which may enhance its growth prospects.
- Analysts are generally bullish on AbbVie and highlighted its potential in the healthcare sector.
- Market fluctuations and stock dips were noted, which may influence short-term performance but could provide buying opportunities.

## Summary
AbbVie shows a strong cumulative return compared to the S&P 500 and has favorable analyst opinions, despite recent price fluctuations indicating potential short-term risks. The company is expanding into new markets, which could contribute positively to future growth.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.